Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

Trial Profile

Study MEA117113: Mepolizumab vs. Placebo as Add-on Treatment for Frequently Exacerbating COPD Patients Characterized by Eosinophil Level

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jun 2017

At a glance

  • Drugs Mepolizumab (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms Study MEA117113
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 May 2017 Preliminary results of two pivotal phase III studies published in a GlaxoSmithKline Media Release
    • 03 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 25 Oct 2016 This trial has been completed in Germany as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top